Literature DB >> 17520758

Office of the Assistant Secretary for Preparedness and Response; HHS Public Health Emergency Medical Countermeasures Enterprise implementation plan for chemical, biological, radiological and nuclear threats. Notice.

.   

Abstract

The United States faces serious public health threats from the deliberate use of weapons of mass destruction (WMD)--chemical, biological, radiological, or nuclear (CBRN)--by hostile States or terrorists, and from naturally emerging infectious diseases that have a potential to cause illness on a scale that could adversely impact national security. Effective strategies to prevent, mitigate, and treat the consequences of CBRN threats is an integral component of our national security strategy. To that end, the United States must be able to rapidly develop, stockpile, and deploy effective medical countermeasures to protect the American people. The HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) has taken a holistic, end-to-end approach that considers multiple aspects of the medical countermeasures mission including research, development, acquisition, storage, maintenance, deployment, and guidance for utilization. Phase one of this approach established the HHS PHEMCE Strategy for Chemical, Biological, Radiological, and Nuclear Threats (HHS PHEMCE Strategy). The HHS PHEMCE Strategy, published in the Federal Register on March 20, 2007, described a framework of strategic policy goals and objectives for identifying medical countermeasure requirements and establishing priorities for medical countermeasure evaluation, development and acquisition. These strategic policy goals and objectives were used to establish the Four Pillars upon which this HHS Public Health Emergency Medical Countermeasures Enterprise Implementation Plan (HHS PHEMCE Implementation Plan) is based. The HHS PHEMCE Implementation Plan considers the full spectrum of medical countermeasures-related activities, including research, development, acquisition, storage/maintenance, deployment, and utilization. The HHS PHEMCE Implementation Plan is consistent with the President's Biodefense for the 21st Century and is aligned with the National Strategy for Medical Countermeasures against Weapons of Mass Destruction.

Entities:  

Mesh:

Year:  2007        PMID: 17520758

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  11 in total

1.  Protecting vulnerable populations from pandemic influenza in the United States: a strategic imperative.

Authors:  Sonja S Hutchins; Benedict I Truman; Toby L Merlin; Stephen C Redd
Journal:  Am J Public Health       Date:  2009-10       Impact factor: 9.308

2.  Considerations in developing medical countermeasures against chemical ocular toxicity.

Authors:  David T Yeung; Houmam Araj; Jill R Harper; Gennady E Platoff
Journal:  Toxicol Lett       Date:  2020-09-08       Impact factor: 4.372

3.  Abstracts of Presentations from the 2020 Trans-Agency Scientific Meeting on Developing Medical Countermeasures to Treat the Acute and Chronic Effects of Ocular Chemical Toxicity, 25-26 February, Bethesda, Maryland.

Authors:  David T Yeung; Houmam Araj; Patrick M McNutt
Journal:  Toxicol Lett       Date:  2020-05-25       Impact factor: 4.372

4.  A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus.

Authors:  Celestine J Thomas; Hedi E Casquilho-Gray; Joanne York; Dianne L DeCamp; Dongcheng Dai; Erin B Petrilli; Dale L Boger; Richard A Slayden; Sean M Amberg; Stephen R Sprang; Jack H Nunberg
Journal:  J Biol Chem       Date:  2010-12-15       Impact factor: 5.157

5.  Supporting Fundamental Chemical Toxicology Research To Inform Medical Countermeasure Developments: The National Institutes of Health Chemical Countermeasures Research Program.

Authors:  David T Yeung; Jill R Harper; Gennady E Platoff
Journal:  Chem Res Toxicol       Date:  2020-03-20       Impact factor: 3.739

6.  siRNA screen for genes that affect Junín virus entry uncovers voltage-gated calcium channels as a therapeutic target.

Authors:  Madakasira Lavanya; Christian D Cuevas; Monica Thomas; Sara Cherry; Susan R Ross
Journal:  Sci Transl Med       Date:  2013-09-25       Impact factor: 17.956

7.  Scientific research and product development in the United States to address injuries from a radiation public health emergency.

Authors:  Andrea L DiCarlo
Journal:  J Radiat Res       Date:  2021-09-13       Impact factor: 2.724

8.  FDA Experience with Medical Countermeasures under the Animal Rule.

Authors:  Paul Aebersold
Journal:  Adv Prev Med       Date:  2011-09-20

9.  Biodefense countermeasures: the impact of Title IV of the US Pandemic and All-Hazards Preparedness Act.

Authors:  Gk Gronvall
Journal:  Emerg Health Threats J       Date:  2008-02-29

10.  Anti-ceramide single-chain variable fragment mitigates radiation GI syndrome mortality independent of DNA repair.

Authors:  Jimmy A Rotolo; Chii Shyang Fong; Sahra Bodo; Prashanth Kb Nagesh; John Fuller; Thivashnee Sharma; Alessandra Piersigilli; Zhigang Zhang; Zvi Fuks; Vijay K Singh; Richard Kolesnick
Journal:  JCI Insight       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.